METABOLIC
Semaglutide
Explore compounded semaglutide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
From $129/mo
ODT (oral dissolving)
Tirzepatide ODT
A compounded tirzepatide and ondansetron dissolving tablet, with formulation-specific clinical review, pharmacy fulfillment and follow-up.
Your treatment plan
From $269/month equivalent
$807 billed every 3 months3-month commitment$299 billed monthly also availableAll fees includedView plan details
- Licensed clinicians
- Compounded by a licensed 503A pharmacy
- No clinic visit
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
Questions before you start?
Compare this treatmentWhat will I pay?
Standard plan price$269 per month equivalent, billed $807 every 3 months. 3-month commitment.
Billing options and renewal
The standard Tirzepatide ODT price is $299 billed monthly, or $807 paid up front every three months ($269 per month equivalent; a three-month commitment). These are recurring prices before any eligible first-order discount. A first-order offer reduces that order only; renewal uses the standard price for the chosen plan. A monthly equivalent is not a monthly charge.
What should I know about this treatment?
A compounded tirzepatide and ondansetron dissolving tablet, with formulation-specific clinical review, pharmacy fulfillment and follow-up.
Read the evidence and its limitationsWhat should I review before starting?
Boxed warning
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, significant gastrointestinal disease, and any glucose-lowering medication are reviewed before prescribing.
A licensed clinician reviews your health history and medications and determines whether treatment is appropriate for you.
Read the full Important Safety InformationHow do I request Tirzepatide ODT online?
Complete the online assessment with your health history, current medications and treatment goals. A licensed clinician reviews the information and decides whether to prescribe. If prescribed, a licensed pharmacy prepares and ships your medication.
See how care worksWhat It Is
Understand the tablet before you choose a path.
This compounded orally disintegrating tablet combines tirzepatide with ondansetron. An ODT is designed to dissolve in the mouth. It is a distinct preparation with its own prescribing considerations.
Your clinician reviews your medical needs, other medicines and the available options before deciding whether this formulation belongs in your care. A preference for tablets alone does not establish a medical reason for compounding.
Studies of approved injections do not establish the absorption, safety or effectiveness of this compounded tablet. It is not an FDA-approved oral version of Mounjaro or Zepbound.
Your prescription supplies the dose and use instructions. Clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging are included in the plan.
Read the evidenceWho It's For
Bring your practical questions into the visit.
01
Questions about injections
If needles, handling or storage concern you, discuss them with your clinician alongside the evidence for the available oral and injectable options.
02
Previous treatment experience
Share the products you have tried, your response and any side effects. That history helps your clinician assess the next step.
03
A routine you can follow
Talk through your day-to-day needs and ask how a prescribed formulation would fit. Clinical suitability comes before choosing a format.
This compounded formulation is not FDA-approved. A clinician evaluates the available treatments and whether an individual medical need supports this preparation. Your formulation and dose are prescribed after review.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
- Type 1 diabetes or insulin-dependent regimens without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Your Plan
Tirzepatide ODT, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Format
- ODT (oral dissolving)
- Strength
- Tirzepatide 3 mg to 12 mg with ondansetron 2 mg
- Total plan quantity
- 90 tablets
- Billed amount
- $807 every 3 months
- Monthly equivalent
- $269 per month
- Commitment
- 3 months
- Monthly option
- $299 billed monthly · 30 tablets total plan quantity
- Fees
- Included in the plan price
Strength describes the preparation. Total plan quantity is the amount included in that plan, not your dose or dosing schedule. Follow the directions on your prescription.
Compounded by a licensed 503A pharmacy
Tirzepatide ODT
ODT (oral dissolving)
From $269
Monthly equivalent. All fees included.
$807 billed every 3 months. 3-month commitment.
- Clinician review of whether an alternate route is documented as appropriate for you
- Compounded orally disintegrating tirzepatide prepared to the individual prescription
- Route-specific prescribing and adjustment rather than injection-dose substitution
- Follow-up tied to response, tolerability, and the wider metabolic plan
$269 /mo equivalent · 3-month commitment
$269/mo equivalent, all-in. Consultation is included in the plan price, not added on top. Consultation, cancellation and refund policy.
What happens when I start?
You'll begin an online assessment for Tirzepatide ODT.
- Tell your clinician about you. Share your goals, health history and current medications.
- Review your plan. Confirm the treatment option, billing interval and total shown in the assessment.
- Get an individual clinical review. Your clinician decides whether to prescribe. If prescribed, a licensed pharmacy fulfills your prescription.
Starting an assessment doesn't guarantee a prescription. How care works
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
*Price reflects a 3-month commitment. See billing details above.
Your subscription renews at your selected billing interval. Cancel through your member dashboard before the next billing date to stop future charges. Cancellation does not refund the current billing period. See cancellation and refund terms.
Have a question about this plan?
Clinical questions
Message your provider about dosing, side effects, your response or changes in your health.
Open patient portalNew to AnthologyRX? Ask our team about getting started.
Care and cost
Clear pricing. Care that follows through.
Your plan brings the clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging together. The consultation is included in your plan price.
- What will I pay at the start and on renewal?
- $299 billed monthly, or $807 paid up front every three months ($269/month equivalent; three-month commitment). These are the standard recurring prices, before any eligible first-order discount. The monthly equivalent is not a monthly charge.
- Does a dose change affect the price?
- The displayed price is for the Tirzepatide ODT plan and selected billing interval. Confirm the prescribed strength, quantity and price before starting or changing treatment. Moving to a different product or formulation can change the cost. Your clinician decides whether a dose change is appropriate.
- How is this formulation different?
- The current dissolving tablet combines tirzepatide with ondansetron. It is a different formulation from an injection or an approved swallowed tablet; their study results do not establish the results of this ODT. Explore our other tirzepatide preparations: Tirzepatide injections or Lower-dose injections with B12. Each requires its own clinical evaluation.
- Who helps when I have a question?
- Use the patient portal for questions about dosing, side effects or changes in your health. AnthologyRX support can help with billing, shipping and portal access.
The people behind your care
Guidance from the first question onward.
Independent clinical care
Licensed clinicians affiliated with Arora Health & Aesthetics, LLC review your health history, medications and goals, then discuss whether Tirzepatide ODT or another approach fits your needs.
Medical information on this page reviewed by Dr. Dylan Russell, MD, Chief Health Officer on . Your prescribing clinician provides your individual care.
Verify Dr. Russell's medical licensePharmacy quality that matters
Prepared to your prescription by a licensed compounding pharmacy. Our partners have verified quality programs covering identity, potency, independent testing and batch documentation.
Compounded preparations are not FDA-approved. Pharmacy quality controls and your clinician's evaluation of treatment evidence each have a role in your care.
Pharmacy & fulfillment
Listed dispensing pharmacy
- The Pharmacy Hub LLCFormulation: Tirzepatide ODTVerify: Florida pharmacy license PH33959
Availability depends on your prescription and location. For pharmacy questions, contact our team.
A direct line for follow-up
Message your provider through the patient portal about dosing, side effects, your response or changes in your health. Contact AnthologyRX support for billing, shipment or portal-access help.
The Evidence
What the research shows
Tirzepatide is one peptide that activates both the GIP and the GLP-1 receptor.
Both native incretin receptors
the GIP and GLP-1 receptors, the targets of the two native incretin hormones
The detail
Tirzepatide is a single peptide that binds to and activates both the GIP receptor and the GLP-1 receptor, the targets of the two native incretin hormones.1
GIP and GLP-1 are gut peptides that produce the incretin effect after nutrient intake.
The detail
GIP and GLP-1 are gut peptides secreted after nutrient intake, GIP from K cells of the upper intestine and GLP-1 from L cells of the lower intestine, and together they produce the incretin effect, the larger insulin secretory response to oral than to intravenous glucose; GLP-1 is also glucagonostatic.2
Labeling says tirzepatide raises insulin, lowers glucagon and delays gastric emptying.
The detail
Approved tirzepatide labeling states that the molecule enhances first- and second-phase insulin secretion and reduces glucagon, both in a glucose-dependent manner, and that it delays gastric emptying, an effect largest after the first dose that diminishes over time.1
Labeling calls GLP-1 an appetite regulator; the GIP contribution rests on animal studies.
The detail
The same class of labeling describes GLP-1 as a physiological regulator of appetite and caloric intake, notes that GIP and GLP-1 receptors are found in areas of the brain involved in appetite regulation, and attributes the further contribution of GIP to food-intake regulation to nonclinical studies, with distribution to appetite-related brain regions shown in animal studies.3
What it does not show
None of the sources above evaluated a compounded preparation.
The detail
Approved-product labeling describes the pharmacokinetics and quality attributes of that finished product. It does not describe the exposure, potency or content of a preparation compounded to an individual prescription, and none of the sources above evaluated such a preparation.4
FDA does not verify the safety, effectiveness or quality of compounded drugs.
The detail
A compounded preparation is not an FDA-approved drug product, and FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed.4
Everything above is mechanism from labeling, not trial results.
The detail
Every statement above is drawn from the clinical pharmacology section of approved labeling, a section separate from the clinical studies section of the same document. This block deliberately describes how the molecule works and does not report what any trial measured.1
Dual agonism is a statement about receptor binding, not about results.
The detail
Dual agonism means one molecule occupies two incretin receptors, a property characterized in vitro through receptor-occupancy analysis and cell signalling assays. It is a statement about receptor binding rather than a claim of results superior to agonism at the GLP-1 receptor alone.5
The central nervous system role of GIP in food intake was established in mice.
The detail
The central nervous system role of GIP receptor signalling in the control of food intake was established in mice, and rodent findings of that kind do not establish human outcomes.6
- FDA-approved tirzepatide injection prescribing information, sections…DailyMed
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018.
- FDA-approved tirzepatide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor… JCI Insight. 2020. In vitro receptor pharmacology.
- Zhang Q, Delessa CT, Augustin R, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body… Cell Metab. 2021.e5. Mouse study.
Important Safety Information
Boxed warning
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. That warning is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, significant gastrointestinal disease, and any glucose-lowering medication are reviewed before prescribing.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
- Use of apomorphine or a known allergy to ondansetron
Serious risks
- Pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Kidney injury related to dehydration
- Hypoglycemia when tirzepatide is used with insulin or insulin secretagogues
Commonly reported
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Because it is a compounded preparation
- This preparation is compounded rather than an FDA-approved finished drug product, so it has no safety database of its own
- Absorption through the oral route differs from subcutaneous injection, so exposure cannot be assumed to match an injectable product
The effects patients report most often are gastrointestinal, most often during titration. The important risks in tirzepatide labeling are listed here. Absorption through the oral route differs from subcutaneous injection, so exposure cannot be assumed to match an injectable product. The prescribing judgment stays with your clinician. The tablet also contains ondansetron, so your clinician should review heart-rhythm risks and interactions with serotonergic medicines. Approved ondansetron labeling warns about QT prolongation and serotonin syndrome. 9
- DailyMed: Ondansetron prescribing information, contraindications and…DailyMed
Questions
Asked and answered.
Explore
More in Metabolic.
METABOLIC
Tirzepatide
Explore compounded tirzepatide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
From $169/mo
METABOLIC
Semaglutide + B12 Microdose
A lower-dose compounded semaglutide and vitamin B12 injection, with individual prescribing, pharmacy fulfillment and follow-up.
From $109/mo
